^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    PDGFRA (Platelet Derived Growth Factor Receptor Alpha)

    i
    Apply
    Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors (NCT04771520)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    01/20/2021
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    PDGFRA
    |
    PDGFRA mutation
    |
    Ayvakit (avapritinib)
    A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL) (NCT06124157)
    Phase 3
    National Cancer Institute (NCI)
    Not yet recruiting
    Last update posted :
    02/14/2025
    Initiation :
    05/29/2025
    Primary completion :
    12/01/2030
    Completion :
    12/01/2030
    ABL1 • KIT • PDGFRA • CD19 • PDGFRB • CSF1R
    |
    CD19 expression
    |
    dasatinib • imatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Starasid (cytarabine ocfosfate)
    Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies (AZURE) (NCT05609942)
    Phase 1
    Blueprint Medicines Corporation
    Active, not recruiting
    Last update posted :
    02/14/2025
    Initiation :
    09/25/2023
    Primary completion :
    01/14/2025
    Completion :
    12/31/2025
    PDGFRA
    |
    KIT mutation • PDGFRA D842V • PDGFRA mutation
    |
    azacitidine • elenestinib (BLU-263)
    Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (AALL1631) (NCT03007147)
    Phase 3
    Children's Oncology Group
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    08/08/2017
    Primary completion :
    09/30/2027
    Completion :
    09/30/2027
    ABL1 • BCR • PDGFRA • PDGFRB • IKZF1 • CSF1R
    |
    BCR-ABL1 fusion • ABL1 fusion
    |
    imatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • vincristine • daunorubicin • dexamethasone • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Hemady (dexamethasone tablets) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexrazoxane • levoleucovorin calcium • prednisolone
    Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015) (LITESPARK-015) (NCT04924075)
    Phase 2
    Merck Sharp & Dohme LLC
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    08/12/2021
    Primary completion :
    06/04/2029
    Completion :
    06/04/2029
    KIT • PDGFRA • VHL • EPAS1
    |
    PDGFRA mutation
    |
    Welireg (belzutifan)
    A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib (NCT04633122)
    Phase 2
    Zai Lab (Shanghai) Co., Ltd.
    Completed
    Last update posted :
    02/10/2025
    Initiation :
    11/25/2020
    Primary completion :
    07/20/2022
    Completion :
    07/20/2022
    KIT • PDGFRA
    |
    KIT mutation • PDGFRA mutation
    |
    imatinib • sunitinib • Qinlock (ripretinib)
    Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (SWOG-S1318) (NCT02143414)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    06/30/2015
    Primary completion :
    06/01/2022
    Completion :
    10/23/2025
    ABL1 • BCR • PDGFRA • FGFR • PDGFRB • CD4 • CSF1R
    |
    ABL2 fusion
    |
    dasatinib • Blincyto (blinatumomab) • methotrexate • vincristine • prednisone • mercaptopurine delayed release (DR6MP) • mercaptopurine • Xatmep (methotrexate oral solution)
    Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT) (NCT01505400)
    Phase N/A
    University Health Network, Toronto
    Active, not recruiting
    Last update posted :
    02/03/2025
    Initiation :
    02/01/2012
    Primary completion :
    01/01/2026
    Completion :
    01/01/2026
    EGFR • HER-2 • PIK3CA • FGFR2 • STK11 • HRAS • PDGFRA • JAK2 • AKT1 • FGFR4 • CTNNB1
    First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST 1) (NCT05489237)
    Phase 1
    IDRx, Inc.
    Recruiting
    Last update posted :
    01/17/2025
    Initiation :
    08/01/2022
    Primary completion :
    04/24/2026
    Completion :
    09/13/2026
    PDGFRA
    |
    KIT mutation • PDGFRA mutation • PDGFRA exon 18 mutation
    |
    sunitinib • IDRX-42
    89Zr-olaratumab Dosimetry in Participants With Soft Tissue Sarcoma (ZOLAR) (NCT06537596)
    Phase 1
    Telix Pharmaceuticals (Innovations) Pty Ltd
    Recruiting
    Last update posted :
    12/19/2024
    Initiation :
    10/31/2024
    Primary completion :
    03/01/2026
    Completion :
    08/01/2026
    PDGFRA
    |
    FOLR1 expression
    |
    Lartruvo (olaratumab)
    Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial (NCT05554341)
    Phase 2
    National Cancer Institute (NCI)
    Suspended
    Last update posted :
    06/10/2024
    Initiation :
    07/14/2023
    Primary completion :
    07/01/2025
    Completion :
    07/01/2025
    PDGFRA
    |
    PDGFRA D842V • KIT L576P • KIT K642E • KIT V559 • KIT V559A • KIT W557
    |
    paclitaxel • Tasigna (nilotinib)
    A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies (NCT05957367)
    Phase 1/2
    Deciphera Pharmaceuticals LLC
    Recruiting
    Last update posted :
    05/31/2024
    Initiation :
    09/28/2023
    Primary completion :
    03/01/2027
    Completion :
    06/01/2027
    BRAF • KIT • PDGFRA
    |
    BRAF V600E • BRAF V600 • KIT mutation • KIT exon 11 mutation • PDGFRA mutation
    |
    Erbitux (cetuximab) • Braftovi (encorafenib) • Qinlock (ripretinib) • inlexisertib (DCC-3116)
    A Study of NB003 in Patients With Advanced Malignancies (NCT04936178)
    Phase 1
    Ningbo Newbay Technology Development Co., Ltd
    Recruiting
    Last update posted :
    05/15/2024
    Initiation :
    08/06/2021
    Primary completion :
    07/31/2025
    Completion :
    12/31/2025
    PDGFRA
    |
    NB003
    Imatinib TDM in GIST (NCT05493215)
    Phase 2
    Reema A. Patel
    Recruiting
    Last update posted :
    04/01/2024
    Initiation :
    03/26/2024
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    KIT • PDGFRA
    |
    KIT mutation • PDGFRA D842V • PDGFRA mutation
    |
    imatinib
    The Efficacy and Safety of Temozolomide in SDH-deficient GIST (NCT05661643)
    Phase 2
    Asan Medical Center
    Recruiting
    Last update posted :
    03/15/2024
    Initiation :
    06/28/2023
    Primary completion :
    12/01/2026
    Completion :
    12/31/2027
    KIT • PDGFRA • ANO1
    |
    temozolomide
    SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry (NCT03452774)
    Phase N/A
    Massive Bio, Inc.
    Recruiting
    Last update posted :
    03/15/2024
    Initiation :
    01/01/2018
    Primary completion :
    12/01/2026
    Completion :
    06/01/2027
    EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703
    |
    HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation
    Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor (NCT05905887)
    Phase 2
    Asan Medical Center
    Recruiting
    Last update posted :
    02/28/2024
    Initiation :
    09/06/2023
    Primary completion :
    08/31/2026
    Completion :
    12/31/2026
    KIT • PDGFRA • ANO1
    |
    KIT mutation
    |
    paclitaxel • imatinib • sunitinib • AiTan (rivoceranib) • Stivarga (regorafenib)
    Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (NCI-2018-03465) (NCT03862157)
    Phase 1/2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    01/10/2024
    Initiation :
    02/27/2019
    Primary completion :
    01/31/2025
    Completion :
    01/31/2025
    ABL1 • BCR • NPM1 • PDGFRA • PDGFRB • CEBPA
    |
    NPM1 mutation • CEBPA mutation • PDGFRA rearrangement
    |
    Venclexta (venetoclax) • azacitidine • pevonedistat (MLN4924)
    Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib. (NCT03944304)
    Phase 2
    Asan Medical Center
    Recruiting
    Last update posted :
    01/01/2024
    Initiation :
    05/27/2019
    Primary completion :
    11/30/2025
    Completion :
    11/30/2025
    KIT • PDGFRA • ANO1
    |
    KIT mutation
    |
    paclitaxel • imatinib • sunitinib • Stivarga (regorafenib)
    French Long Term Registry With Longitudinal Follow up of PDGFRA D842V-GIST Patients (AVIATOR2020) (NCT04927260)
    Phase N/A
    Centre Leon Berard
    Active, not recruiting
    Last update posted :
    12/25/2023
    Initiation :
    03/31/2021
    Primary completion :
    04/30/2024
    Completion :
    12/31/2024
    PDGFRA
    |
    PDGFRA D842V
    |
    Ayvakit (avapritinib)
    A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies (NCT02571036)
    Phase 1
    Deciphera Pharmaceuticals LLC
    Completed
    Last update posted :
    12/13/2023
    Initiation :
    11/01/2015
    Primary completion :
    04/29/2022
    Completion :
    04/29/2022
    KIT • PDGFRA
    |
    KIT mutation • PDGFRA mutation • KIT amplification
    |
    Qinlock (ripretinib)
    Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST (NCT02413736)
    Phase 3
    Heikki Joensuu
    Active, not recruiting
    Last update posted :
    11/09/2023
    Initiation :
    05/01/2015
    Primary completion :
    05/01/2026
    Completion :
    05/01/2033
    KIT • PDGFRA • ANO1
    |
    KIT mutation • PDGFRA mutation
    |
    imatinib
    Oncogenetic Panel and Integrated Clinical Data Registry Study for Wild Type Gastrointestinal Stromal Tumor Patients (GIST) (NCT04821895)
    Phase N/A
    National Health Research Institutes, Taiwan
    Recruiting
    Last update posted :
    11/09/2023
    Initiation :
    08/28/2021
    Primary completion :
    12/31/2025
    Completion :
    12/31/2029
    KIT • PDGFRA
    |
    PDGFRA mutation • KIT wild-type • PDGFR wild-type
    Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT. (NCT02272998)
    Phase 2
    Sameek Roychowdhury
    Active, not recruiting
    Last update posted :
    09/18/2023
    Initiation :
    02/24/2015
    Primary completion :
    11/17/2022
    Completion :
    11/17/2023
    FLT3 • ABL1 • RET • PDGFRA • FGFR
    |
    FGFR mutation • FGFR fusion
    |
    Iclusig (ponatinib)
    A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST) (ALT GIST) (NCT02365441)
    Phase 2
    Australasian Gastro-Intestinal Trials Group
    Active, not recruiting
    Last update posted :
    07/07/2023
    Initiation :
    06/30/2015
    Primary completion :
    12/31/2023
    Completion :
    12/31/2023
    KIT • PDGFRA • ANO1
    |
    PDGFRA mutation
    |
    imatinib • Stivarga (regorafenib)
    A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling (BLU-285-3101) (NCT04773782)
    Phase 1/2
    Blueprint Medicines Corporation
    Recruiting
    Last update posted :
    06/15/2023
    Initiation :
    02/24/2022
    Primary completion :
    12/31/2024
    Completion :
    04/30/2025
    KIT • PDGFRA
    |
    PDGFRA mutation
    |
    Ayvakit (avapritinib)
    Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma (NCT01817751)
    Phase 2
    Virginia Commonwealth University
    Active, not recruiting
    Last update posted :
    04/06/2023
    Initiation :
    04/11/2013
    Primary completion :
    08/27/2020
    Completion :
    10/30/2027
    PDGFRA
    |
    PDGFRA expression
    |
    sorafenib • sildenafil
    Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (SeliGIST) (NCT04138381)
    Phase 1/2
    Grupo Espanol de Investigacion en Sarcomas
    Active, not recruiting
    Last update posted :
    03/27/2023
    Initiation :
    08/16/2019
    Primary completion :
    04/16/2023
    Completion :
    04/16/2023
    KIT • PDGFRA
    |
    PDGFRA mutation
    |
    imatinib • Xpovio (selinexor)
    Tagraxofusp (SL-401) in Patients With CMML or MF (Study 0314) (NCT02268253)
    Phase 2
    Stemline Therapeutics, Inc.
    Completed
    Last update posted :
    03/21/2023
    Initiation :
    12/01/2014
    Primary completion :
    03/07/2023
    Completion :
    03/07/2023
    PDGFRA • JAK2 • PDGFRB • PCM1
    |
    FGFR1 rearrangement
    |
    Elzonris (tagraxofusp-erzs)
    Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST (NCT05751733)
    Phase N/A
    Xiangya Hospital of Central South University
    Recruiting
    Last update posted :
    03/02/2023
    Initiation :
    02/01/2023
    Primary completion :
    01/01/2026
    Completion :
    01/01/2027
    PDGFRA
    |
    dasatinib • imatinib • sunitinib • AiTan (rivoceranib)
    Impact of ctDNA in Cancer Early Detection and STAS Evaluation in Patients With GGOs (NCT05187767)
    Phase N/A
    University of Roma La Sapienza
    Recruiting
    Last update posted :
    11/08/2022
    Initiation :
    04/01/2022
    Primary completion :
    01/01/2024
    Completion :
    10/01/2024
    EGFR • HER-2 • KRAS • BRAF • ALK • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • ROS1 • IDH1 • IDH2 • FGFR3 • FGFR1 • HRAS • PDGFRA • NOTCH1 • SMAD4 • CTNNB1 • ERBB4 • DDR2
    Safety and Efficacy of ThisCART19A Bridging Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia (NCT05576181)
    Phase 1
    Fundamenta Therapeutics, Ltd.
    Not yet recruiting
    Last update posted :
    10/12/2022
    Initiation :
    10/15/2022
    Primary completion :
    01/22/2025
    Completion :
    07/22/2025
    ABL1 • BCR • PDGFRA • FGFR • JAK2 • PDGFRB • IKZF1 • JAK1 • CD22 • IL7R • TCF3 • SH2B3
    |
    CD19 expression
    |
    cyclophosphamide • etoposide IV • ThisCART19A
    (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors (NCT02508532)
    Phase 1
    Blueprint Medicines Corporation
    Completed
    Last update posted :
    06/21/2022
    Initiation :
    08/01/2015
    Primary completion :
    03/06/2020
    Completion :
    06/03/2021
    KIT • PDGFRA
    |
    PDGFRA D842V • PDGFRA mutation
    |
    Ayvakit (avapritinib)
    Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With R/R B-ALL (FT400-004) (NCT05350787)
    Phase 1
    Zhejiang University
    Recruiting
    Last update posted :
    04/28/2022
    Initiation :
    03/18/2022
    Primary completion :
    03/30/2024
    Completion :
    04/30/2024
    ABL1 • BCR • PDGFRA • FGFR • JAK2 • PDGFRB • IFNG • IL6 • IKZF1 • TNFA • JAK1 • IL2 • IL7R • IL10 • TCF3 • TGFB1 • IL17A • SH2B3 • IL1B
    |
    CD19 expression
    Molecular Biomarkers Predicting Early Development of Endometrial Carcinoma (NCT05273099)
    Phase N/A
    Università degli Studi di Ferrara
    Recruiting
    Last update posted :
    04/12/2022
    Initiation :
    03/01/2022
    Primary completion :
    03/01/2023
    Completion :
    12/01/2023
    EGFR • HER-2 • KRAS • BRAF • ALK • TP53 • PIK3CA • FLT3 • ABL1 • NRAS • FGFR2 • PTEN • IDH1 • IDH2 • FGFR3 • FGFR1 • STK11 • NPM1 • HRAS • CDKN2A • RB1 • PDGFRA • NOTCH1 • JAK2 • GNAQ • AKT1 • KDR • MLH1 • GNA11 • PTPN11 • SMAD4 • CTNNB1 • FBXW7 • CDH1 • SMARCB1 • ERBB4 • JAK3 • GNAS • CSF1R • HNF1A
    |
    JAK3 mutation
    SSG XXV: The Stop-GIST Trial; Discontinuation of Imatinib in Patients With Oligo-metastatic GIST (NCT02924714)
    Phase N/A
    Oslo University Hospital
    Suspended
    Last update posted :
    02/18/2022
    Initiation :
    01/01/2017
    Primary completion :
    11/01/2022
    Completion :
    11/01/2022
    KIT • PDGFRA • ANO1
    |
    PDGFRA mutation
    |
    imatinib
    Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors (ZJGIST-01) (NCT04933669)
    Phase 2
    First Affiliated Hospital of Zhejiang University
    Recruiting
    Last update posted :
    10/12/2021
    Initiation :
    09/07/2021
    Primary completion :
    12/31/2029
    Completion :
    12/31/2029
    KIT • PDGFRA • ANO1
    |
    KIT mutation • KIT exon 11 mutation • KIT exon 9 mutation • KIT positive • PDGFRA mutation • KIT exon 13 mutation • KIT exon 17 mutation
    |
    imatinib
    A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST) (NCT03158103)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Completed
    Last update posted :
    04/30/2021
    Initiation :
    04/15/2017
    Primary completion :
    04/28/2021
    Completion :
    04/28/2021
    KIT • PDGFRA
    |
    PDGFR wild-type
    |
    Mektovi (binimetinib) • Turalio (pexidartinib)